UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

HDL cholesterol and protective factors in atherosclerosis

Circulation (New York, N.Y.), 2004-06, Vol.109 (23 Suppl 1), p.III8-II14

2004

Volltextzugriff (PDF)

A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism

The New England journal of medicine, 2009-04, Vol.360 (18), p.1851-1861

2009

Volltextzugriff (PDF)

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

The New England journal of medicine, 2008-11, Vol.359 (21), p.2195-2207

2008

Volltextzugriff (PDF)

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

The Lancet (British edition), 2009-04, Vol.373 (9670), p.1175-1182

2009

Volltextzugriff (PDF)

Comparing a novel machine learning method to the Friedewald formula and Martin-Hopkins equation for low-density lipoprotein estimation

PloS one, 2020-09, Vol.15 (9), p.e0239934-e0239934

2020

Volltextzugriff (PDF)

Benefits of Statins in Elderly Subjects Without Established Cardiovascular Disease: A Meta-Analysis

Journal of the American College of Cardiology, 2013-12, Vol.62 (22), p.2090-2099

2013

Volltextzugriff (PDF)

Update on statins: 2003

Circulation (New York, N.Y.), 2004-08, Vol.110 (7), p.886-892

2004

Volltextzugriff (PDF)

Evaluation of Lipids, Drug Concentration, and Safety Parameters Following Cessation of Treatment With the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients With or at High Risk for Coronary Heart Disease

The American journal of cardiology, 2014, Vol.113 (1), p.76-83

2014

Volltextzugriff (PDF)

Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia

JAMA cardiology, 2020-10, Vol.5 (10), p.1124

2020

Volltextzugriff (PDF)

HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial

The Lancet (British edition), 2010-07, Vol.376 (9738), p.333-339

2010

Volltextzugriff (PDF)

Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib[S]

Journal of lipid research, 2013-02, Vol.54 (2), p.467-472

2013

Volltextzugriff (PDF)

A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis

Journal of the American College of Cardiology, 2005-05, Vol.45 (10), p.1611-1619

2005

Volltextzugriff (PDF)

High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease

The American heart journal, 2002-12, Vol.144 (6), p.S33-S42

Gotto, Antonio M.

2002

Volltextzugriff (PDF)

Design of the DEFINE trial: Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib

The American heart journal, 2009-10, Vol.158 (4), p.513-519.e3

2009

Volltextzugriff (PDF)

Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

Circulation (New York, N.Y.), 2000-02, Vol.101 (5), p.477-484

2000

Volltextzugriff (PDF)

Baseline Characteristics of Participants in the JUPITER Trial, A Randomized Placebo-Controlled Primary Prevention Trial of Statin Therapy Among Individuals With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein

The American journal of cardiology, 2007-12, Vol.100 (11), p.1659-1664

2007

Volltextzugriff (PDF)

Statin therapy and the elderly: SAGE advice?

Circulation (New York, N.Y.), 2007-02, Vol.115 (6), p.681-683

Gotto, Jr, Antonio M

2007

Volltextzugriff (PDF)

Candidate genetic analysis of plasma high-density lipoprotein-cholesterol and severity of coronary atherosclerosis

BMC medical genetics, 2009-10, Vol.10 (1), p.111-111, Article 111

2009

Volltextzugriff (PDF)

Effects of High-Dose Atorvastatin on Cerebrovascular Events in Patients With Stable Coronary Disease in the TNT (Treating to New Targets) Study

Journal of the American College of Cardiology, 2006-11, Vol.48 (9), p.1793-1799

2006

Volltextzugriff (PDF)

A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events

Annals of internal medicine, 2005-01, Vol.142 (2), p.95

2005

Volltextzugriff (PDF)

Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease

The New England journal of medicine, 2010-12, Vol.363 (25), p.2406-2415

2010

Volltextzugriff (PDF)

HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events

The New England journal of medicine, 2007-09, Vol.357 (13), p.1301-1310

2007

Volltextzugriff (PDF)

Lipids, Safety Parameters, and Drug Concentrations After an Additional 2 Years of Treatment With Anacetrapib in the DEFINE Study

Journal of cardiovascular pharmacology and therapeutics, 2014-11, Vol.19 (6), p.543-549

2014

Volltextzugriff (PDF)

The 9p21 susceptibility locus for coronary artery disease and the severity of coronary atherosclerosis

BMC cardiovascular disorders, 2009-01, Vol.9 (1), p.3-3, Article 3

2009

Volltextzugriff (PDF)

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

The Lancet (British edition), 2010-02, Vol.375 (9716), p.735-742

2010

Volltextzugriff (PDF)

1 – 25 von 75

Suche als RSS-Feed

Aktive Filter

ThemaAged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(72)
Mit Volltextzugriff
(67)

Publikationsform

Artikel
(75)

Sprache

Englisch
(75)

Erscheinungsjahr

n.n

Thema

Humans
(75)
Science & Technology
(69)
Life Sciences & Biomedicine
(68)
Male
(67)
Middle Aged
(66)
Female
(65)
Cardiac & Cardiovascular Systems
(41)
Cardiovascular System & Cardiology
(41)
Biological And Medical Sciences
(39)
Medical Sciences
(39)
Adult
(38)
Cholesterol
(31)
Cholesterol, Ldl - Blood
(31)
Double-Blind Method
(27)
Anticholesteremic Agents - Therapeutic Use
(26)
Risk Factors
(26)
Cardiovascular Disease
(25)
Treatment Outcome
(23)
Hydroxymethylglutaryl-Coa Reductase Inhibitors - Therapeutic Use
(21)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

HDL cholesterol and protective factors in atherosclerosis

A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

Comparing a novel machine learning method to the Friedewald formula and Martin-Hopkins equation for low-density lipoprotein estimation

Benefits of Statins in Elderly Subjects Without Established Cardiovascular Disease: A Meta-Analysis

Update on statins: 2003

Evaluation of Lipids, Drug Concentration, and Safety Parameters Following Cessation of Treatment With the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients With or at High Risk for Coronary Heart Disease

Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia

HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial

Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib[S]

A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis

High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease

Design of the DEFINE trial: Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib

Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

Baseline Characteristics of Participants in the JUPITER Trial, A Randomized Placebo-Controlled Primary Prevention Trial of Statin Therapy Among Individuals With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein

Statin therapy and the elderly: SAGE advice?

Candidate genetic analysis of plasma high-density lipoprotein-cholesterol and severity of coronary atherosclerosis

Effects of High-Dose Atorvastatin on Cerebrovascular Events in Patients With Stable Coronary Disease in the TNT (Treating to New Targets) Study

A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events

Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease

HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events

Lipids, Safety Parameters, and Drug Concentrations After an Additional 2 Years of Treatment With Anacetrapib in the DEFINE Study

The 9p21 susceptibility locus for coronary artery disease and the severity of coronary atherosclerosis

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

Aktive Filter

Suchergebnisse filtern